Literature DB >> 24218281

Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer.

Deniz Tural1, Fatih Selcukbiricik, Özcan Yıldız, Olgun Elcin, Sibel Erdamar, Sabri Güney, Fuat Demireli, Evin Büyükünal, Süheyla Serdengeçti.   

Abstract

BACKGROUND: The study populations of previous preoperative chemoradiotherapy (pre-CRT) studies have consisted of mixed clinical stages, such as cT3-cT4 and/or cN positive. For this reason, it has not been possible to demonstrate whether pre-CRT is of benefit for individual subgroups.
METHODS: The medical records of 137 rectal cancer patients with clinical stage T3, N0 disease who received either pre-CRT or postoperative chemoradiotherapy (post-CRT) between 2002 and 2011 were retrospectively analyzed. The regimen of pre-CRT consisted of slow fluorouracil (5FU) infusion and that of post-CRT consisted of bolus 5FU and leucovorin concurrent with radiation.
RESULTS: Following pre-CRT, significant downstaging was achieved. However, administration of pre-CRT did not influence the type of surgical resection in tumours ≤5 cm distant from the anal verge (p = 0.14). Pathological complete response was achieved in 16 % of the patients in the pre-CRT group. The local recurrence rate (LRR) at 5 years was 5.7 % in the pre-CRT and 11.1 % in the post-CRT groups (p = 0.04). The distant recurrence rate (DRR) at 5 years was 76 % and 77 % in the pre-CRT and post-CRT groups, respectively (p = 0.1). Overall survival was similar in two groups (74.8 % vs. 75.3 %, p = 0.3).
CONCLUSIONS: The treatment of stage T3, N0 rectal cancer patients with pre-CRT followed by surgery decreased LRR, but did not improve DRR or OS as compared with surgery followed by post-CRT in our patient cohort.

Entities:  

Mesh:

Year:  2013        PMID: 24218281     DOI: 10.1007/s10147-013-0636-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  23 in total

1.  Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis.

Authors:  Shandra Bipat; Afina S Glas; Frederik J M Slors; Aeilko H Zwinderman; Patrick M M Bossuyt; Jaap Stoker
Journal:  Radiology       Date:  2004-07-23       Impact factor: 11.105

2.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

3.  The impact of preoperative chemoradiotherapy on advanced low rectal cancer.

Authors:  Ping-Sheng Kao; Shih-Ching Chang; Ling-Wei Wang; Rheun-Chuan Lee; Wen-Yi Liang; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kai Jiang; Shung-Haur Yang; Huann-Sheng Wang; Jen-Kou Lin
Journal:  J Surg Oncol       Date:  2010-12-01       Impact factor: 3.454

4.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

5.  Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

Authors:  Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

6.  cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted.

Authors:  José G Guillem; Juan A Díaz-González; Bruce D Minsky; Vincenzo Valentini; Seung-Yong Jeong; Miguel A Rodriguez-Bigas; Claudio Coco; Rebecca Leon; José L Hernandez-Lizoain; José J Aristu; Elyn R Riedel; Donato Nitti; W Douglas Wong; Salvatore Pucciarelli
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

7.  Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy.

Authors:  Antonio I Picon; Harvey G Moore; Stephen S Sternberg; Bruce D Minsky; Philip B Paty; David Blumberg; Stuart H Quan; W Douglas Wong; Alfred M Cohen; Jose G Guillem
Journal:  Int J Colorectal Dis       Date:  2003-06-03       Impact factor: 2.571

8.  The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.

Authors:  Koen C M J Peeters; Corrie A M Marijnen; Iris D Nagtegaal; Elma Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm Rutten; Lars Pahlman; Bengt Glimelius; Jan Willem Leer; Cornelis J H van de Velde
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

Review 9.  Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer.

Authors:  Wim P Ceelen; Yves Van Nieuwenhove; Kjell Fierens
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

10.  Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

Authors:  David Sebag-Montefiore; Richard J Stephens; Robert Steele; John Monson; Robert Grieve; Subhash Khanna; Phil Quirke; Jean Couture; Catherine de Metz; Arthur Sun Myint; Eric Bessell; Gareth Griffiths; Lindsay C Thompson; Mahesh Parmar
Journal:  Lancet       Date:  2009-03-07       Impact factor: 79.321

View more
  8 in total

1.  Therapeutic results of abdominoperineal resection in the prone jackknife position for T3-4 low rectal cancers.

Authors:  Xiang Hu; Liang Cao; Jian Zhang; Pin Liang; Ge Liu
Journal:  J Gastrointest Surg       Date:  2014-11-04       Impact factor: 3.452

2.  Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer.

Authors:  F Alongi; S Fersino; R Mazzola; A Fiorentino; N Giaj-Levra; F Ricchetti; R Ruggieri; G Di Paola; M Cirillo; S Gori; M Salgarello; G Zamboni; G Ruffo
Journal:  Clin Transl Oncol       Date:  2016-06-07       Impact factor: 3.405

3.  The efficacy and safety of different radiotherapy doses in neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Authors:  Yongchun Zhang; Peng Jiang; Hui Zhu; Bin Dong; Hanxiao Zhai; Zhiying Chen
Journal:  J Gastrointest Oncol       Date:  2021-08

4.  Which is the best postoperative chemotherapy regimen in patients with rectal cancer after neoadjuvant therapy?

Authors:  Peng Gao; Yong-xi Song; Jing-xu Sun; Xiao-wan Chen; Ying-ying Xu; Jun-hua Zhao; Xuan-zhang Huang; Hui-mian Xu; Zhen-ning Wang
Journal:  BMC Cancer       Date:  2014-11-27       Impact factor: 4.430

5.  The survival and clinicopathological differences between patients with stage IIIA and stage II rectal cancer: An analysis of 12,036 patients in the SEER database.

Authors:  Ben Huang; Shaobo Mo; Liang Zhu; Tianhong Xu; Guoxiang Cai
Journal:  Oncotarget       Date:  2016-11-29

6.  Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A meta-analysis.

Authors:  Jinfeng Zhu; Wei Zeng; Lei Ge; Xinhui Yang; Qisan Wang; Haijiang Wang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  Effects of Neoadjuvant Radiotherapy on Postoperative Complications in Rectal Cancer: A Meta-Analysis.

Authors:  Jianguo Yang; Yajun Luo; Tingting Tian; Peng Dong; Zhongxue Fu
Journal:  J Oncol       Date:  2022-01-05       Impact factor: 4.375

8.  Short-course neoadjuvant chemoradiotherapy and surgery are beneficial in Chinese patients: A retrospective study.

Authors:  Ming Jun Huang; Xiao Dong Wang; Yan Jie Hu; Jie Yang; Ka Li
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.